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BACKGROUND: Successful blastocyst implantation requires the differentiation of human endometrial stromal cells
(HESC), a process known as decidualization. Activin A, a transforming growth factor b (TGFb) superfamily member,
enhances HESC decidualization and localizes to decidual cells in human endometrium. Other TGFb superfamily
members, including BMP2, BMP4, BMP7, GDF5, GDF8, GDF11, TGFbs and Nodal, may also play a role during
decidualization. This study aimed to identify these TGFb family members in human endometrium, and to determine
whether they are involved in human decidualization. METHODS: Protein localization of TGFb family members was
examined in secretory phase human endometrium and ﬁrst trimester decidua by immunohistochemistry. mRNA
expression was examined in HESC. Activin inhibitors (Activin-M108A/SB431542) with differing speciﬁcities for
the other TGFb members under consideration were applied during HESC decidualization in vitro. The secretion
levels of potential TGFb superfamily members were measured during decidualization, and recombinant proteins
added to examine their effect. RESULTS: This study has identiﬁed BMP2, BMP4, BMP7, GDF5, GDF8 and
GDF11 but not Nodal in secretory phase human endometrium, but only BMP2, GDF5 and TGFb1 protein were
detected in decidual cells. All ligands except Nodal were expressed by cultured HESC. Both inhibitors signiﬁcantly
reduced decidualization validating the role of activin, but potentially also other TGFb members, during decidualiza-
tion. BMP2 and TGFb1 secretion increased during HESC decidualisation and exogenous administration of these pro-
teins signiﬁcantly enhanced decidualization in vitro. CONCLUSIONS: Like activin, BMP2 and TGFb1 are likely to be
involved in HESC decidualization. This is the ﬁrst study to identify and localize BMP4, BMP7, GDF5, GDF8 and
GDF11 in secretory phase human endometrium. Understanding the factors critical for the implantation process is
needed for improving fertility and pregnancy outcomes.
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Introduction
Throughout each menstrual cycle the human endometrium
undergoes morphological and physiological changes, in prep-
aration for pregnancy should the cycle include conception
(Loke et al., 1995). An absolute requirement for successful
implantation is the differentiation and proliferation of endo-
metrial stromal cells into enlarged, phenotypically different
decidual cells, a process termed endometrial decidualization
(Tang et al., 1994; Salamonsen et al., 2003). This process is
initiated near the spiral arterioles (Bell, 1991), and occurs
under the inﬂuence of progesterone (Psychoyos, 1973),
although cAMP appears to be essential for priming the
endometrial stromal cells to the actions of progesterone;
hence both pathways are absolutely required for decidualiza-
tion (Gellersen and Brosens, 2003). It is now clear that the
decidualization response is mediated by a complex array of
bioactive molecules, including IL-11, prostaglandin E2,
relaxin and activins (Frank et al., 1994; Robb et al., 1998;
Jones et al., 2002; Dimitriadis et al., 2005).
The transforming growth factor b (TGFb) superfamily is a
large family of proteins that encompasses the sub-families
TGFbs, activins, bone morphogenetic proteins (BMPs) and
growth differentiation factors (GDFs). Overall, this superfam-
ily of proteins exhibits functional diversity, with biological
roles in cell differentiation, proliferation, apoptosis and tissue
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Activins consist of two b subunits, bA and bB, that homo/
heterodimerize to form activin A, activin B and activin AB,
respectively. The activin b subunits are produced in the gland-
ular epithelium during the proliferative and secretory phases,
but in stromal cells only following decidualization during the
mid-late secretory phase (Otani et al., 1998; Jones et al.,
2000; Mylonas et al., 2004). High levels of dimeric activin A
are secreted by cAMP-treated endometrial stromal cells.
Addition of activin A to decidualizing cells in vitro signiﬁ-
cantly increased the secretion of prolactin (PRL) and
IGFBP-1 (decidual cell markers), suggesting activin A drives
decidualization (Jones et al., 2002; Tierney and Giudice,
2004). This decidualization response can be neutralized by
follistatin, the naturally occurring activin antagonist (Jones
et al., 2002; Tierney and Giudice, 2004). In addition to its
tight regulation of activin (Shimonaka et al., 1991; Schneyer
et al., 1994), follistatin can also bind and regulate other
TGFb members including the BMPs and GDFs (Table I).
BMPs have been identiﬁed in the rodent uterus (Cunningham
et al., 1995;Ozkaynak et al., 1997; Fitzpatrick et al.,1998; Zhao
et al., 1999; Ying and Zhao, 2000; Erickson et al., 2004; Lee
et al., 2007; Li et al., 2007). Inpregnant mice the temporospatial
localization of BMPs 2, 4, 6 and 7 suggested roles during
pregnancy (Ying and Zhao, 2000). BMP2 is present within the
decidual area at implantation sites (Ying and Zhao, 2000;
Li et al., 2007) and plays a role in decidualization in vitro
(Li et al., 2007). Importantly, conditional ablation of uterine
BMP2 in mice resulted in ineffective decidualization and
disrupted pregnancy outcome (Lee et al., 2007). In a human
model of endometrial stromal cell (HESC) decidualization
in vitro, BMP2 mRNA increased during decidualization and
addition of BMP2 to cultures accelerated PRL mRNA
expression (a measure of the extent of decidualization). BMP2
protein has not been examined in vivo in human endometrial
tissue. The only GDFs identiﬁed in the uterus are GDF9 and
GDF10, detected by northern analysis in both human and
mouse (Cunningham et al., 1995; Fitzpatrick et al., 1998;
Zhao et al., 1999): no studies have shown GDF proteins.
TGFb isoforms (1–3), which cannot bind follistatin, have
also been localized in human endometrial stroma (Jones et al.,
2006), although it is not clear whether any isoform is speciﬁc
to decidualized cells or increases as the cells decidualize.
The TGFbs transmit signal through the TGFb type I, II and
III receptors, all of which are present on endometrial stromal
cells (Chegini et al., 1994; Dumont et al., 1995). Microarray
studies have demonstrated increases in both TGFb1a n d
TGFb2 mRNA with HESC decidualization in vitro (Popovici
et al., 2000; Tierney et al., 2003), while in women treated
with medroxyprogesterone acetate (MPA) for 10 days, stromal
mRNA and protein increased for TGFb3b u tn o tT G F b1( R e i s
et al., 2002). Whether the TGFbs play a functional role during
human decidualization remains unknown.
Given that the TGFbsuperfamily of proteins are such common
and crucial differentiative and proliferative factors, it is surprising
that very few members of the family, including the GDFs and
BMPs, have been examined in the human endometrium, particu-
larly in the mid-secretory phase when differentiation of stromal
cells is initiated. The high level of redundancy between TGFb
family members and the promiscuity of receptor–ligand inter-
actions would suggest that it is likely that a number of other
family members are involved in decidualization and in the
other processes occurring in this highly dynamic tissue.
In this study, the presence of BMPs (BMP2, BMP4, BMP7),
GDFs (GDF5, GDF8/Myostatin, GDF11), Nodal and TGFbs
were examined in vivo by immunohistochemistry in secretory
phase endometrial tissue, and in vitro for mRNA expression in
both non-decidualized and decidualized HESC. Inhibitors with
different speciﬁcities were administered to HESC to elucidate
whether activin is the major family member driving decidualiza-
tion or whether other family groupings (BMPs, GDFs, TGFbs)
might equally contribute to the process. As these are secreted
factors, individual ligands were measured in conditioned
medium from non-decidualized and decidualized HESC to
assess whether they increased with decidualization. The effect
of the secreted ligands on decidualization was also examined.
It is important to identify which TGFb members are important
during decidualization since this process is critical for implan-
tation and the establishment of pregnancy.
Table I. Inhibitors of TGFb superfamily: ligand–receptor blocking.
Ligand Follistatin Activin-M108A SB431542
Binds ligands and blocks
association with type II receptors
Activin type II receptor
(ActRIIA/B) antagonist
Inhibitor of TGFb and
activin type I receptors
Activin A þþþþ (Schneyer et al., 2003) þþ (Harrison et al., 2004) þþþ (Inman et al., 2002)
Activin B þþ (Schneyer et al., 2003) þþþ
a þþþ (Inman et al., 2002)
GDF 8 þþ (Amthor et al., 2004) þþþ
a þþþ (Inman et al., 2002)
GDF11 þþ (Gamer et al., 1999) þþþ
a þþþ (Inman et al., 2002)
BMP2 þ (Iemura et al., 1998) 22
BMP4 þ (Iemura et al., 1998; Glister et al., 2004) 22
BMP7 þ (Iemura et al., 1998; Glister et al., 2004) (2/þ) 2
GDF5 (þ) 22
Nodal 2 (þþþ) þþþ (Inman et al., 2002)
TGFb1 22 þþþ (Inman et al., 2002)
TGFb2 22 þþþ (Inman et al., 2002)
TGFb3 22 þþþ (Inman et al., 2002)
aC.A. Harrison (unpublished observations); (), anticipated activity.
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Tissue collections
Endometrial biopsies (n ¼ 18) were collected by dilatation and
curettage from fertile women who were scheduled for tubal ligation
or were undergoing testing for tubal patency. Tissues were assessed
by a pathologist and had no obvious endometrial pathology.
The women had no steroid treatment or other medication for at least
2–3 months before the collection of tissue. Written and informed
consent was obtained from all women participating in the study, and
the protocols were approved by Monash Medical Centre Human
Ethics Committee.
Immunohistochemistry
Immunohistochemical analysis was performed using a total of nine
endometrial tissue biopsies from fertile women, conﬁrmed by Noyes
criteria (Noyes et al., 1975) as mid-late secretory phase tissue (POD
6–12). For each of the antibodies, activin bA and bB, BMP2,
BMP4, BMP7, GDF5, GDF8, GDF11, Nodal and TGFb1, n ¼ 4–5
different tissue biopsies were used. For immunolocalization in ﬁrst
trimester placental tissue (kindly provided by Professor Euan
Wallace, Obstetrics and Gynaecology, Monash University, Mel-
bourne, Australia), n ¼ 2 different biopsies were used per antibody.
Brieﬂy, 5 mm sections of formalin-ﬁxed, parafﬁn-embedded tissues
were dewaxed and rehydrated. For each antibody an antigen retrieval
step was required, which involved microwave exposure or trypsin
digestion (0.01% in CaCl2for 10 min at 378C). Endogenous hydrogen
peroxidase activity was quenched using 3% H2O2 in dH2O for 10 min
at room temperature. Non-speciﬁc binding was prevented by pre-
incubation of tissue sections with a non-immune block [5% fetal
calf serum (FCS), 2% normal human serum in 0.1% Tween/
Tris-buffered saline (TBS) with addition of 10% normal horse
serum for BMP2, BMP4, BMP7, GDF5, GDF8; 10% normal swine
serum for Nodal; normal goat serum for activin bA and bB,
GDF11, TGFb1]. Primary antibodies were against activin bA and
activin bB (400 and 600 mg/ml, respectively; both gifts provided by
W. Vale, Salk Institute, La Jolla, CA, USA); BMP2, BMP4, BMP7,
GDF5, GDF8, Nodal (200 mg/ml; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA); GDF11 (1 mg/ml; Orbigen, San Diego, CA,
USA); TGFb1( mg/ml; Abcam, Cambridge, UK). Speciﬁcity for
these antibodies has been previously published (Nadiri et al., 2004;
Kiyono and Shibuya, 2003; Mendler et al., 2000; McPherron et al.,
1999; Garba and Relinger, 2001). For GDF5 and Nodal, the speciﬁcity
has been shown by western blot analysis (unpublished observation).
Antibodies were diluted to 2–4 mg/ml in the non-immune block and
applied overnight (18–20 h) at 48C. A non-immune goat/rabbit/
mouse IgG (R&D Systems Incorporated, Minneapolis, MN, USA)
was used at a matching concentration to the primary antibody and
was included for each tissue. After stringent washing with high salt
TBS and 0.6% Tween 20 (BioRad Laboratories, Hercules, CA, USA),
detection of positive binding was performed by the sequential appli-
cation of the appropriate secondary antibody diluted in non-immune
block and avidin–biotin–peroxidase conjugate (Dako, Glostrup,
Denmark). This was followed by the substrate diaminobenzidine
(Dako) for between 3 and 5 min. Sections were counterstained with
Harris’ hematoxylin (Sigma Chemical Company, St Louis, MO,
USA), dehydrated, and mounted from Histosol with DPX mounting
medium (BDH Laboratory Supplies, Poole, UK). Immunostaining was
analysed by two independent observers for staining intensity and
heterogeneity in each of the endometrial compartments (glandular and
luminal epithelium; stroma, including decidualized stromal cells;
vasculature).
Stromal cell isolation and culture
Tissue biopsies ranging from Days 10–21 were used for in vitro
decidualization studies. HESC were isolated from tissue by enzymatic
digestion and ﬁltration as described previously (Dimitriadis et al.,
2002). Brieﬂy, tissue was ﬁnely minced with scissors and digested by
bacterial collagenase type III (Worthington Biochemical Corporation,
Freehold, NJ, USA) at a concentration of 45 IU/ml, in the presence
of 3.5 mg/ml deoxyribonuclease (DNase; Boehringer Mannheim
Biochemica, Mannheim, Germany). After 30–45 min of agitation at
378C, the digested tissue was ﬁltered sequentially through 45 and
10 mm nylon ﬁlters to remove glands. Cell suspensions were
centrifuged at 1500 rpm for 5 min. Cells were plated at a density of
5   10
6 in a 75 cm
2 ﬂask and grown to conﬂuency in DMEM and
Ham’s F12 medium (1:1) (DMEM/F12) (Trace Biosciences, Sydney,
Australia), supplemented with 1% PSF (penicillin, streptomycin
and fungizone) (Commonwealth Serum Laboratories, Melbourne,
Australia) and 10% charcoal stripped FCS (csFCS) (Thermo Scientiﬁc,
Maple Plain, USA). Approximately 30 min after plating, medium
containing non-attached epithelial cells was removed and replaced
with fresh medium. This results in a .97% pure stromal cell culture
(Dimitriadis et al., 2002).
In vitro decidualization
Conﬂuent HESC were rinsed with phosphate-buffered saline, trypsi-
nized and replated into 24-well plates using DMEM/F12 and 10%
csFCS. Once conﬂuent, HESC were washed with DMEM/F12 and
the medium replaced with a serum-free medium containing
DMEM/F12 and a serum-free mix (SFM) including transferrin
(10 mg/ml; Sigma), sodium selenite (25 ng/ml; Sigma), linoleic
acid (10 nmol/L; Sigma), bovine serum albumin (0.1%; Sigma) and
insulin (5 mg/ml; Actrapid, Novo-Nordisk Pharmaceuticals Pty Ltd,
Sydney, Australia) for 48 h prior to treatment addition. HESC were
decidualized by two distinct methods as previously described
(Dimitriadis et al., 2005). For the inhibitor, mRNA expression and
protein secretion studies, 0.5 mM cAMP (Sigma) was added to
medium for 4–6 days. Alternatively, when exogenous proteins were
added, cells were decidualized with E2 (10
28 M; Sigma) and MPA
(10
27M; Sigma) for 8 days. All media were replaced every 48–72 h.
RNA extraction and cDNA synthesis
Total RNA was extracted from non-decidualized and decidualized
HESC from two separate biopsies at Day 4–6 using the RNeasy
Minikit (Qiagen Sciences, Germantown, MD, USA), according to the
manufacturer’s instructions. RNA from positive control tissues was
extracted by homogenization in Trizol reagent (Qiagen Sciences,
Clifton Hill, Victoria, Australia), according to the manufacturer’s
instructions, with the exception of an additional chloroform extraction
step to minimize carryover of phenol into the precipitate. The control
tissues used were: term placenta (activin bA, bB, GDF11, TGFb1,
-2, -3); pregnant mouse endometrium (BMP2); mature rat ovary
(BMP4, GDF5); cycling mouse endometrium (BMP7); mouse heart
(GDF8); JEG3 cells (Nodal). All samples were treated with RNase-free
DNase (Ambion, Austin, TX, USA) to remove the possibility of
genomic DNA contamination. RNA samples were then analysed by
spectrophotometry to determine RNA concentration, yield and purity.
Total RNA (1 mg) was reverse transcribed at 468C for 1.5 h in 20 ml
reaction mixture using 100 ng random hexanucleotide primers and
6 IU AMV reverse transcriptase (Roche, Castle Hill, Australia) in the
presence of cDNA synthesis buffer (Roche), 1 mmol/l dNTPs
(Roche),10 mmol/ldithiothreitol(Roche),10 IUribonucleaseinhibitor
(RNasin; Promega, Annandale, Australia). The resultant cDNA mix-
tures were heated at 958C for 3 min before storage at 2208C. Negative
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RNA samples were reverse transcribed in triplicate for each condition
(non-decidualized and decidualized) with the successful conversion to
cDNA monitored by 18S expression (data not shown).
RT–PCR
Messenger RNA expression for all named TGFb superfamily ligand
members was determined using a conventional PCR block cycler
(Hybaid, Middlesex, UK). All ligands (excluding Nodal), used a 1 ml
aliquot of RT product, to be ampliﬁed in a total volume of 40 ml
using 4 ml of RT single strength PCR buffer (10 mmol/lT r i s – H C l ,
1.5 mmol/lM g C l 2, 50 mmol/l KCl, pH 8.3; Roche), 2.5 mmol/l
dNTPs (Gibco, Melbourne, Australia), 0.5 pmol/ml sense and antisense
primers (Sigma Genosys Australia Pty Ltd, Castle Hill, Australia) and
2.5 IU Taq DNA polymerase (Roche). For Nodal, 1 mlo fR Tw a s
ampliﬁed in a total of 50 ml using the KOD-Taq PCR kit (Bioron,
Germany), which included 10  PCR KOD Hot Start buffer, 2 mM
dNTPs, 0.5 pmol/ml primers, 2 mM MgSO4 and 2.5 IU Taq DNA
polymerase (Roche). For all ligands, the PCR was performed in three
stages as follows: the ﬁrst stage involved 948Cf o r5 m i n ,xCf o r
1 min, where x is the annealing temperature for the individual primer
pairs (see Supplementary data) and 728C for 3 min; the second stage
involved 35–40 cycles of 948Cf o r1m i n ,xCf o r1m i n ,a n d7 2 8C
for 1 min; and the ﬁnal stage was 728C for 7 min. PCR products
including positive controls were analysed by electrophoresis on a 2%
agarose gel (Roche) and stained with ethidium bromide. Bands of
interest were excised from the gel, puriﬁed (DNA puriﬁcation kit,
Qiagen) and directly sequenced to conﬁrm their identity.
Inhibitor experiments
For examination of the effect of inhibitors on decidualization, cells
(from n ¼ 10 biopsies) were plated at a density of 2.5   10
5/well in
24-well plates until conﬂuent, and then equilibrated in serum-free
medium containing SFM for 48 h. This was designated Day 0 and
ﬁrst day of treatments. HESC were exposed to varying doses of
either the inhibitor Activin-M108A (M108A) (0.39 1.56, 6.25 and
25 nM) (Harrison et al., 2004, 2006) or the inhibitor SB431542
(1.25, 2.5, 5 and 10 mM) (TOCRIS Bioscience, Northpoint, UK). Fol-
lowing 1 h incubation with either inhibitor, 0.5 mM cAMP (Sigma)
was added as decidualizing stimulus. Each treatment was performed
in triplicate wells of a 24-well plate and the experiments ran for
4–6 days with media collection and replenishment (including inhibi-
tors) every 48–72 h. In each case, the ﬁnal medium collection rep-
resented the ﬁnal 48 h. Each experiment included a medium-only
and a cAMP-only control. Cells were photographed for morphological
analysis and cells from triplicate wells were pooled for trypan blue cell
exclusion to check cell viability at the end of each experiment. Five
separate cultures were conducted for each inhibitor.
TGFb superfamily assays
Culture medium from triplicate wells from three tissue biopsies (n ¼ 3
separate decidualization experiments) were collected, pooled and con-
centrated 5-fold to measure BMP2 (ELISA; R&D Systems), BMP4,
BMP7, TGFb1 and TGFb2 (ELISA; Ray BioTech., Norcross, GA,
USA) according to the manufacturer’s instructions. Mean sensitivities
of the assays were: BMP4, 15 pg/ml, BMP7, 10 pg/ml, TGFb1,
80 pg/ml, TGFb2, 15 pg/ml, with intra-assay CV ,10% and inter-
assay CV ,12% for each assay. Mean sensitivity for BMP2 was
11 pg/ml and intra- and inter-assay variabilities were 2.6 and 6.3%,
respectively. TGFb1 and TGFb2 ELISAs measured only the activated
protein form and required activation steps prior to assay. Dimeric
activin A secretion from stromal cells was measured by Activin A
Immunoﬂuorometric Assay (IFMA) (Harrison et al., 2006). The
working range of the assay is 0.03–3 ng/well, with a sensitivity of
0.03 ng/well. All assays were read at 450 nm.
Addition of exogenous BMP2 and TGFb1 during decidualization
HESC from three separate cultures were decidualized using E2 and
MPA as described above, in the presence of varying doses of either
recombinant human (rh) BMP2 (5, 50, 500 ng/ml; R&D Systems)
or TGFb1 0.5, 5, 50 ng/ml; PeproTech Inc., NJ, USA) added every
48 h with media and decidualizing stimulus replenishment. At Day
8, cells were morphologically assessed and conditioned media were
collected for PRL measurement.
PRL and protein assays
PRL production by HESC was assayed in duplicate by ELISA (Bio-
clone Australia Pty Ltd, Sydney, Australia) to determine the extent
of decidualization (Dimitriadis et al., 2002). Media collected at the
end of the experiment were concentrated 5-fold for PRL measurement.
A quality control sample (culture medium from a single endometrial
cell culture) was included in every assay. The lower detection limit
of the assay was 50 mIU/l. The inter- and intra-assay variablilities
were 5.3 and 3.0%, respectively. PRL concentrations (mIU/l) were
corrected for the amount of protein (mg/ml) determined using the
Bradford reagent.
Statistical analysis
Data were expressed as mean+SEM. Statistical signiﬁcance for
inhibitor studies was determined following conﬁrmation of normal
distribution, by one-way ANOVA followed by Dunnett’s multiple
comparisons test. Data from ELISA and recombinant protein studies
were analysed by Student’s t-test. A P-value of ,0.05 was considered
statistically signiﬁcant.
Results
Localization of TGFb superfamily ligands in human
endometrium and ﬁrst trimester decidua
All TGFb superfamily members studied, except Nodal, were
detected in mid-late secretory endometrium and ﬁrst trimester
decidua. As previously described (Jones et al., 2000), activin A
and activin B were localized to the morphologically distinct
decidual cells (Fig. 1A and B), glandular and luminal epithelial
cells and some leukocytes (data not shown). Some glands had
punctate staining for BMP2 (Fig. 1C), but BMP2 was most
strongly stained in decidual cells in mid-late secretory endome-
trium (Fig. 1D). In ﬁrst trimester decidua, BMP2 protein was
detected inboth the decidual cells (Fig.1E, inset) and glandular
epithelium, while the vessels were devoid of stain (Fig. 1E).
GDF5 protein was observed in the decidualized stromal cells
(Fig. 1F and G) and was very low in the glands (Fig. 1F) and
luminal epithelium (data not shown). Similarly, GDF5 was
very strongly expressed by the decidua of ﬁrst trimester pla-
centa, as well as the glandular epithelium (Fig. 1H, inset).
TGFb1 was present in decidualized stromal cells (Fig. 1I and
J), with minimal staining evident in the glandular epithelium
(Fig. 1I). As previously described (Graham et al., 1992),
TGFb1 was detected in decidual cells and extravillous tropho-
blasts of ﬁrst trimester placenta (Fig. 1K). BMP4 was not
detected in the glandular or luminal epithelium, but was
present in the cytoplasm of both non-decidualized and
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trimester placenta, BMP4 was reduced in the decidual cells,
but strongly produced by the glandular epithelium (Fig. 1N,
inset). BMP7 was detected in the stroma and not in the
glands in mid-late secretory endometrium (Fig. 1O). Stromal
staining for BMP7 did not appear to be decidual cell speciﬁc,
however, in highly decidualized tissue stronger ‘vesicle stain-
ing’ was evident (Fig. 1P). Similar but faint punctate staining
for BMP7 was detected around spiral arterioles of ﬁrst trime-
ster placenta, but not speciﬁcally in decidual cells (Fig. 1Q,
inset). BMP7 was also strongly localized to glandular and
luminal epithelium (Fig. 1Q). GDF8 immunostaining in
mid-late secretory endometrium showed minimal glandular
and luminal epithelial staining, and intense stromal cell cyto-
plasmic staining, in both non-decidualized and decidualized
cells (Fig. 1R). GDF11 immunolocalized to glandular
epithelium and endothelial cells, but was very low in the
stroma (Fig. 1S). GDF8 and GDF11 in ﬁrst trimester placenta
showed similar staining patterns to BMP4 (data not shown).
No immunoreactive Nodal was detected in late secretory endo-
metrium (Fig. 1T), although the immunostaining protocol was
veriﬁed by positive staining in term placenta (not shown).
TGFb superfamily mRNA expression in non-decidualized
and decidualized HESC
By RT–PCR, mRNA expression was evident for activin bA,
activin bB, BMP2, BMP4, BMP7, GDF5, GDF8, GDF11,
TGFb1, TGFb2 and TGFb3 in both non-decidualized and
decidualized HESC (Fig. 2). Nodal mRNA was undetectable
in both. As conventional RT–PCR was used, only the pre-
sence/absence of each gene was assessed. Positive control
PCR products (Fig. 2; see supplementary data) conﬁrmed
Figure 1: Localization of TGFb superfamily members during decidualization in mid-late secretory endometrium and ﬁrst trimester decidua.
Photomicrographs are representatives of immunostaining for activin A (A), activin B (B), BMP2 (C–E), GDF5 (F–H), TGFb1( I–K), BMP4
(L–N), BMP7 (O–Q), GDF8 (R), GDF11 (S), Nodal (T). In mid-late secretory endometrium; scale bar ¼ 100 mm (C, F, I, L, O, R, S); scale
bar ¼ 10 mm (D, G, J, M, P, T). In ﬁrst trimester decidua; scale bar ¼ 200 mm (E, H, K, N, Q); inserts show higher power images of same
tissue (E, H, K, N, Q). Negative controls for each antibody are shown in inserts (C, F, I, L, O, R, S, T). Arrows highlight decidualized (D), non-
decidualized (ND) stromal cells and glands (G).
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transcriptase was omitted (Fig. 2).
Activin-M108A and SB431542 signiﬁcantly decreases
PRL secretion during HESC decidualization
To establish whether HESC decidualization could be blocked
or reduced, the newly developed activin type II receptor antag-
onist, Activin-M108A or the type I receptor kinase inhibitor,
SB431542 were used in an in vitro decidualization model
with PRL secretion, a marker of decidualization, as the end-
point. These inhibitors affect activin and various other TGFb
family members (see Table I). Cells maintained in medium
alone (non-decidualized) showed non-detectable PRL levels
over the ﬁnal 48 h of culture (Fig. 3). In contrast, cells
treated with cAMP secreted PRL (mean 372.6+145.5 mIU/
l), and morphologically changed from elongated spindle-
shaped cells to typical enlarged polygonal cells demonstrating
successful decidualization, as previously described (Dimi-
triadis et al., 2002). Stromal cells cultured with cAMP and
Activin-M108A showed a signiﬁcant dose-dependent decrease
in PRL secretion at 0.39, 1.56 and 6.25 nM with no further
decrease at 25 nM (Fig. 3A). At the 25 nM dose, a 60%
reduction in PRL secretion was seen compared with cAMP-
treated cells without inhibitor, which was similar to deciduali-
zation reduction seen with follistatin. Similarly cells
co-cultured with cAMP and SB431542 showed a dose-
dependent decrease in PRL secretion. Addition of SB431542
at a concentration of 1.25 mM signiﬁcantly reduced PRL
secretion compared with cAMP-only treated cells (Fig. 3B).
Further signiﬁcant decreases were observed with doses
ranging from 2.5–10 mM (Fig. 3B). At 10 mM, SB431542
reduced PRL secretion by 77% compared with cAMP alone
(Fig. 3B). Higher doses were not tested. When either inhibitor
(Activin-M108A or SB431542) was administered to cells in the
absence of cAMP, PRL was not detected in culture medium. In
addition, cell viability was tested using the trypan blue exclu-
sion method at the end of the experiment and was found to
not differ between treatments with medium-only, cAMP and
either inhibitor. Microscopic visualization indicated cell
morphology was not altered by inhibitor use, suggesting this
effect was not due to toxicity to cells.
Secretion of activin A, TGFb1, BMP2 and BMP4, but not
TGFb2 or BMP7 from non-decidualized and decidualized
HESC in vitro
TGFb ligands are active as secreted proteins. Therefore we
measured BMP2, BMP4, BMP7, TGFb1, TGFb2 from three
different cultures by ELISA and activin A by IFMA (n ¼ 1) in
Figure 2: mRNA expression for TGFb superfamily members by
decidualized and non-decidualized HESC.
HESC were either non-decidualized or decidualized with cAMP for 7
days. Total RNA was extracted from cells for RT–PCR. Representa-
tive products demonstrating Activin bA, Activin bB, BMP2, BMP4,
BMP7, GDF5, GDF8, GDF11, TGFb1, TGFb2, TGFb3 and Nodal
mRNA are shown in non-decidualized (ND) and cAMP-decidualized
(D) HESC; þve¼positive control; 2RT¼negative control. Data
shown is from a single experiment, which is representative of 2 inde-
pendent culture experiments. Figure 3: Activin-M108A and SB43 154 inhibitors signiﬁcantly
decrease HESC decidualization.
Conﬂuent stromal cells were cultured for 4–5 days with cAMP, with
medium changes every 2–3 days. (A) M108A was added at doses
0.39, 1.5, 6.25 and 25 nM to cAMP-treated cultures. (B) SB431542
was added at doses 1.25, 2.5, 5 and 10 mM. Controls (not decidua-
lized; ND) and cAMP (decidualized; D). PRL secretion from cells
was used as a marker of decidualization, and values were corrected
for total protein. All data (mean+SEM) is expressed as % change
from control (100%). Results are combined data from triplicate
wells of ﬁve independent experiments for each inhibitor. *P , 0.05
and **P , 0.01 compared with cAMP alone.
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dimeric activin A secreted from decidualized (1.9 ng/10
6cells)
compared with non-decidualized cells (0.43 ng/10
6cells),
supporting previous published data from our laboratory (Jones
et al., 2002). Non-decidualized and decidualized HESC secreted
BMP2, TGFb1 and BMP4, each in the range of 5–20 pg/10
6
cells (Fig. 4). BMP7 and TGFb2 levels were below the sensitivity
of the assays (data not shown). Decidualized stromal cells
secreted signiﬁcantly higher amounts of BMP2 and TGFb1c o m -
pared with non-decidualized cells (TGFb12 0 . 6 +3.8 versus
14+3.1 pg/10
6cells; BMP2 17.2+2.32 versus 8.44+1.5 pg/
10
6cells) (Fig. 4). BMP4 secretion was increased slightly with
decidualization (6.9+2.17 versus 10.1+3.45 pg/10
6cells),
but this was not signiﬁcant (Fig. 4). Western blot analysis was
performed for GDF5, GDF8, GDF11 and TGFb3u s i n g1 0 0 –
150 mg of cell lysates from non-decidualized and decidualized
HESC; however, these proteins were below the level of detection.
Positive controls (GDF5—rat heart and human term placenta;
TGFb3—human term placenta; GDF8 and GDF11—recombi-
nant human myostatin/GDF8 and recombinant human GDF11,
respectively; data not shown) validated the technique.
Exogenous BMP2 and TGFb1 increases HESC
decidualization in vitro
To assess whether addition of rhBMP2 and/or rhTGFb1t o
HESC enhances decidualization in vitro, cells were decidua-
lized with E2 and MPA under serum-free conditions for 8
days and PRL secretion measured. At Day 8, PRL secretion
from non-decidualized cells was minimal but was increased
when cells were decidualized (Fig. 5). When rhBMP2 (5, 50
or 500 ng/ml) was added to decidualizing HESC, PRL
secretion was signiﬁcantly increased at the 50 ng/ml dose
compared with the decidualized control (P , 0.05). The
addition of rhTGFb1 at 0.5, 5 or 50 ng/ml to decidualizing
HESC, however this was only signiﬁcant at the 0.5 ng/ml dose
(P , 0.01) compared with decidualized cells alone.
Due to the variability of endometrial biopsies only one dose
for each BMP2 and TGFb1 has resulted in a signiﬁcant
promotion of decidualisation. Also as the rhTGFb1 is known
to be quite potent, this result could be explained by the fact
that at the higher doses it might be negatively affecting the
response, for example receptor and downstream signalling
disturbances.
Discussion
This is the ﬁrst study to identify BMP2, BMP4, BMP7, GDF5,
GDF8 and GDF11 protein in secretory phase human endome-
trium and show the mRNA expression of these ligands in
cultured HESC. In addition, the current study has immunoloca-
lized BMP2, TGFb1 and GDF5 protein to decidualized stromal
cells, and provided further evidence for a role for secreted
activin, BMP2 and TGFb1 in decidualization through the use
of novel inhibitors and a well-established ex vivo decidualiza-
tion model.
Decidualization of endometrial stromal cells is a pivotal event
in the preparation for blastocyst implantation. Although this
process is governed by hormonal regulation, it is becomingly
Figure 5: Effect of exogenous BMP2 and TGFb1 on PRL secretion
from HESC.
Cells were untreated or treated with E2 (10
–8 M), MPA (10
–7 M)
alone or combined with recombinant human (rh) BMP2 (5–500 ng/
ml) (A), rhTGFb1 (0.5–50 ng/ml) (B) for 8 day. PRL was measured
in cultured medium from the last 48 h of treatment. Data are rep-
resented as percent fold change from control (decidualized; D)
deﬁned as 100%. ND, non-decidualized HESC. Results are combined
data from triplicate wells of three independent cultures. *P , 0.05 and
**P , 0.01 compared with D.
Figure 4: BMP2, TGFb1 and BMP4 protein secretion by HESC
during decidualization.
BMP2, BMP4 and TGFb1 protein were measured in culture medium
from non-decidualized (dark) and decidualized (grey) cells at Day 4 of
culture. Results are combined data from n ¼ 3 independent culture
experiments and data (mean+SEM) is represented as % difference
from control (non-decidualized cells; deﬁned as 100%). *P , 0.05
and **P , 0.01 compared to control.
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kines and growth factors, are essential in ensuring this process
occurs successfully such that endometrial stromal cells are
differentiated into the implantation-favourable decidual cells.
The identiﬁcation of BMP2, TGFb1 and GDF5 protein in mid-
secretory human endometrial tissue, together with the increased
secretion of both BMP2 and TGFb1f r o ms t r o m a lc e l l sf o l l o w -
ing decidualization, suggests these TGFb family members are
hormonally regulated and important for decidualization.
The ﬁnding that BMP2 secretion from HESC increases as
they decidualize in vitro and that addition of rhBMP2 further
drives decidualization as determined by secretion of PRL,
extends the recent study (Li et al., 2007), which showed an
increase of BMP2 mRNA with decidualization in a similar
model and of PRL mRNA following treatment of HESC with
rhBMP2. This is important given that translation and secretion
do not necessarily follow increases in mRNA. The inhibitor
M108A which acts primarily on those ligands acting through
the activin type 11 receptor (Table I) is not known to block
the action of BMP2 which acts through the BMP type II recep-
tor (BMPRII). Therefore, the inability of M108A to fully block
the decidualization process suggests that factors other than
activins and GDFs are likely to be important to this process:
BMP2 is a likely candidate.
Interestingly in mice, uterine-speciﬁc conditional ablation of
BMP2 resulted in uterine stromal disruption and an inability to
undergo normal decidual reactions and pregnancy progression
(Lee et al., 2007). Our demonstration of BMP2 in human endo-
metrium in vivo with the strongest immunostaining in decidua-
lized cells in the mid-late secretory phase and in the decidua of
early pregnancy, conﬁrms the biological relevance in women.
Given this data in conjunction with our functional studies of
human decidualization, there appears to be little doubt that
BMP2 is an important mediator of both mouse and human
decidualization.
This study also demonstrates, for the ﬁrst time, the presence
of GDF5 in human endometrium and ﬁrst trimester placenta
where it is intensely and speciﬁcally stained in the decidual
cells. GDF5 is best known for its role in early chondrogenesis
and joint formation, being involved ininducing cartilage differ-
entiation, growth and maturation (Mikic, 2004), as well as bone
formation and angiogenesis (Yamashita et al., 1997). Differen-
tiation and angiogenesis are the main events of decidualization.
Unfortunately, assays for GDF5 were not available to measure
the secretion from decidualized cells. The decrease in decidua-
lization seen following administration ofM108A was not likely
to be due to GDF5 blockade, as this ligand has a relatively low,
if any, afﬁnity for the activin type II receptor. Future studies
should address whether GDF5 has a functional role in decidua-
lization, whether it be in promoting differentiation or in the for-
mation of associated blood vessels to support the blastocyst in
early pregnancy and throughout gestation.
Although the TGFbs have been previously detected in the
human endometrium, the information regarding their role
during decidualization is contentious, as studies report con-
trasting effects on PRL production by endometrial stroma
and during decidualization in vitro (Kubota et al., 1997; Kim
et al., 2005). We showed here that under serum-free conditions,
TGFb1 secretion increases during cAMP-induced decidualiza-
tion in vitro. Microarray studies have likewise shown increased
TGFb1 and TGFb2 mRNA when cAMP or progesterone is
used as decidual stimuli (Popovici et al., 2000; Tierney
et al., 2003). The protein for both isoforms localizes to
stromal cells in human endometrium throughout the menstrual
cycle (Gold et al., 1994; Godkin and Dore, 1998), although
decidualized stromal cells were not shown. In contrast, the
present study identiﬁed TGFb1 protein in decidualized
stromal cells in human endometrium, and its secretion
increased in cAMP-decidualized HESC. Administration of
SB431542, which effectively blocks the TGFbs as well as acti-
vins by blocking their structurally similar ALK5 and ALK4
receptors (Inman et al., 2002), resulted in a 77% reduction in
decidualization, a greater decrease than that seen with
M108A (this study) and follistatin (Tierney and Giudice,
2004). This, along with our demonstration that addition of
TGFb1 during progesterone-induced decidualization enhances
decidualization, provides convincing evidence to suggest
TGFb1 is important during decidualization. The level of
activated TGFb2 was undetectable by ELISA in cAMP-
decidualized endometrial stromal cells, and therefore this
ligand is unlikely to contribute to the decidual response.
The identiﬁcation of BMP4, BMP7, GDF8 and GDF11
during the mid-secretory phase is also an important ﬁnding.
In addition to decidualization, there are many remodelling pro-
cesses occurring in the endometrium during this time. Both
BMP4 and GDF8 protein showed intense immunolocalization
to the cytoplasm of the stroma, irrespective of whether or not
the cells were decidualized. This was veriﬁed for BMP4 by
the minimal difference in secretion levels between non-
decidualized and decidualized cells in vitro. BMP4 mRNA
expression has been localized to the vascular endothelial
cells in pregnant mice (Ying and Zhao, 2000), and in the non-
pregnant rat uterus, where it is constitutively expressed
throughout the cycle (Erickson et al., 2004). This differs to
the localization of BMP4 protein shown here in human endo-
metrium. It may be that the mRNA localized to blood vessels
in the rodent studies is not translated into functional protein.
GDF8 (more commonly referred to as Myostatin) is a negative
regulator of skeletal muscle, but more recently has been shown to
be involved in glucose metabolism (McPherron and Lee, 2002),
particularlyin placenta (Mitchell et al., 2006). This study veriﬁed
the presence of GDF8 protein in ﬁrst trimester placenta, and
showed for the ﬁrst time its presence in secretory phase endome-
trium and in HESC. Given the lack of speciﬁc decidual staining it
is unlikely that the response from M108A inhibitor was due to
blocking GDF8 in HESC, even though the predominant receptor
for GDF8 isthe activin type IIreceptor. The presence of GDF8 in
non-muscular tissue and organs is rare and future experiments
should determine whether it has a role in endometrial biology
as it does throughout gestation in the placenta.
Vesicular staining for BMP7 (or Osteogenic protein-1;
OP-1) was evident in highly decidualized cells during the
secretory phase of human endometrium with minimal staining
in selected glandular and luminal epithelial cells. OP-1 has
been identiﬁed in the uterine epithelium of non-pregnant
mice and rat uterus (Ozkaynak et al., 1997; Erickson et al.,
Stoikos et al.
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In pregnant mice, however, BMP7 mRNA was detected in the
decidualizing stromal cells surrounding the blastocyst with no
staining in the epithelial cells (Ying and Zhao, 2000). In the
present study, BMP7 secretion from HESC was undetectable
by ELISA, making it difﬁcult to assess whether it may have
a functional role during decidualization.
In conclusion, this study has identiﬁed that a wide range of
TGFb ligands are presentinmid-late secretory human endome-
trium but of these, in addition to activins, only BMP2, GDF5
and TGFb1 increase in stromal cells as they undergo decidua-
lization. BMP2 and TGFb1, along with activins, are important
in driving the decidualization process. Functions for the
remaining ligands remain to be determined but they are
likely to participate in the extensive tissue remodelling that
occurs in this highly dynamic tissue as it prepares for blastocyst
implantation and pregnancy.
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